Boston Scientific considering sale of snake venom unit

Boston Scientific (NYSE: BSX) is considering a sale process for its snake venom unit, which could fetch upwards of $1 billion, per multiple reports.

Why it matters: Because snake antivenom products, like Boston Scientific's CroFab, are the sort of niche things you never think about until that unfortunate moment when it's all you can think about.